NCT06027242 Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
| NCT ID | NCT06027242 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Taiwan University Hospital |
| Condition | Gastric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2023-02-21 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2023-02-21 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Eligibility Criteria
Inclusion Criteria: * adult gastric cancer receiving gastrectomy Exclusion Criteria: * Hepatic insufficiency * Renal insufficiency * can not tolerate oral or enteral feeding 7 days after gastrectomy * can not receive computed tomograph * can not waer the wearable devices
Contact & Investigator
Jin-Ming Wu, MD
PRINCIPAL INVESTIGATOR
National Taiwan University Hospital
Frequently Asked Questions
Who can join the NCT06027242 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06027242 currently recruiting?
Yes, NCT06027242 is actively recruiting participants. Contact the research team at wujm0531@gmail.com for enrollment information.
Where is the NCT06027242 trial being conducted?
This trial is being conducted at Taipei, Taiwan.
Who is sponsoring the NCT06027242 clinical trial?
NCT06027242 is sponsored by National Taiwan University Hospital. The principal investigator is Jin-Ming Wu, MD at National Taiwan University Hospital. The trial plans to enroll 120 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.